Pamidronate Disodium NDC 61703-325

NDC codes

FDA NDC Directory

Product NDC (as listed)61703-325Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61703-0325Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61703-325-18	61703032518	1 VIAL, SINGLE-DOSE in 1 CARTON (61703-325-18) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Jul 28, 2003

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pamidronate Disodium
Generic name (nonproprietary): pamidronate disodium
Active ingredients: Pamidronate disodium — 6 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Hospira, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075841
Marketing start: Jul 28, 2003
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 61703-325_d1f55dd9-cc5b-4162-81be-53736ffbb5a7SPL ID d1f55dd9-cc5b-4162-81be-53736ffbb5a7SPL set ID 9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23RxCUI 1737449, 1737451, 1737453UNII 8742T8ZQZA
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461703032518 followed by a unit qualifier and the quantity

Package 61703-0325-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 14, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be h…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075841

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075841
Product	Strength	Form · route	Labeler	Product NDC
Pamidronate Disodium	Pamidronate disodium 3 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-324
Pamidronate Disodium	Pamidronate disodium 9 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-326